Dianthus Therapeutics(DNTH.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Dianthus Therapeutics
DNTH.US
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
1.944 T
DNTH.USMarket value -Rank by Market Cap -/-

Financial Score

25/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking205/397
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-28.57%E
    • Profit Margin-4104.78%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY-42.64%E
    • Net Profit YoY-88.32%E
    • Total Assets YoY63.01%A
    • Net Assets YoY61.72%A
  • Cash ScoreD
    • Cash Flow Margin-2.44%D
    • OCF YoY-42.64%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio5.37%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026 | TTIPF Stock News

    Thiogenesis Therapeutics presented interim data from its Phase 2 (EU) study of TTI-0102 for MELAS at Mitocon 2026. The study showed significant improvement in fatigue, with a 10% reduction in MFIS scores for treated patients. Weight-based dosing of approximately 60 mg/kg/day achieved optimal exposure and tolerability, supporting its use in future trials. The findings indicate TTI-0102's potential in improving mitochondrial energy metabolism and reducing oxidative stress, with implications for upcoming studies in related conditions.

    StockTitan·
    US
    DNTH
    -0.82%
    US
    TTRX
    +2.75%
    US
    FBT
    -1.17%
    StockTitan·
    US
    DNTH
    -0.82%
    US
    TTRX
    +2.75%
    US
    FBT
    -1.17%

    17:31 ET Cystinosis Market to Grow at a Substantial Growth Rate of 5.1% During the Forecast Period (2025-2034) | DelveInsight

    DelveInsight's report indicates that the cystinosis market is projected to grow at a rate of 5.1% from 2025 to 2034, with a market size of USD 250 million in 2024. The U.S. will dominate this market, accounting for 84% of the total. Current treatments are primarily cysteamine-based, but emerging therapies like TTI-0102 and DFT383 aim to improve disease management and patient outcomes. Increased awareness, early diagnosis, and the launch of new therapies are key factors driving market growth.

    prnewswire·
    US
    FBT
    -1.17%
    US
    BBH
    -0.45%
    US
    IBB
    -1.30%
    prnewswire·
    US
    FBT
    -1.17%
    US
    BBH
    -0.45%
    US
    IBB
    -1.30%

    Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 47.4% in December

    Dianthus Therapeutics, Inc. (NASDAQ:DNTH) experienced a significant increase in short interest in December, rising 47.4% to 6,136,786 shares. The short-interest ratio is currently 8.2 days, with 17.2% of shares short sold. The stock traded at $44.10, with a 1-year range of $13.36 to $46.59. Recent insider sales totaled 216,538 shares valued at $8.28 million. Institutional investors hold 47.53% of the stock, and analysts have set target prices ranging from $46.00 to $63.00, with ratings varying from "outperform" to "sell."

    Market Beat·
    US
    DNTH
    -0.82%
    Market Beat·
    US
    DNTH
    -0.82%

    Dianthus Therapeutics to Present at J.P. Morgan Healthcare Conference

    Dianthus Therapeutics Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2026. CEO Marino Garcia will provide a corporate overview at 3:00 p.m. PST and will hold one-on-one meetings with investors. A webcast of the presentation will be available on their website.

    Reuters·
    US
    DNTH
    -0.82%
    Reuters·
    US
    DNTH
    -0.82%

    Leads Biolabs and DNTH initiate trial of LBL-047 in SLE

    Leads Biolabs and Dianthus Therapeutics (DNTH) have initiated a Phase I clinical trial for LBL-047 in healthy volunteers and patients with systemic lupus erythematosus (SLE). The trial will assess the pharmacokinetics, safety, and tolerability of LBL-047, a bifunctional fusion protein targeting BDCA2 and TACI. The trial has a two-part, placebo-controlled, double-blind, randomised, dose-escalation design. Leads Biolabs and DNTH formed an exclusive global partnership in 2025, with DNTH obtaining global rights, excluding Greater China, to develop and commercialise LBL-047, known as DNTH212 outside Greater China.

    WorldPharmaceuticals·
    US
    DNTH
    -0.82%
    WorldPharmaceuticals·
    US
    DNTH
    -0.82%
    © 2026 Longbridge｜Disclaimer